Biomarkers in Patients With Acute Myeloid Leukemia
|ClinicalTrials.gov Identifier: NCT01138319|
Recruitment Status : Completed
First Posted : June 7, 2010
Last Update Posted : May 6, 2015
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in patients with acute myeloid leukemia.
|Condition or disease||Intervention/treatment|
|Leukemia||Genetic: DNA analysis Genetic: mutation analysis Genetic: polymerase chain reaction Other: laboratory biomarker analysis|
- To determine whether clonally expanded somatic mitochondrial DNA mutations are associated with acute myeloid leukemia.
OUTLINE: Genomic DNA from blood samples obtained at diagnosis, remission, and relapse are analyzed for mitochondrial DNA mutations via PCR.
|Study Type :||Observational|
|Actual Enrollment :||18 participants|
|Official Title:||Mitochondrial Mutations and AML|
|Study Start Date :||February 2009|
|Actual Primary Completion Date :||March 2010|
- Association between clonally expanded somatic mitochondrial DNA mutations and acute myeloid leukemia
Biospecimen Retention: Samples With DNA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01138319
|Principal Investigator:||Jason H. Bielas, PhD||Fred Hutchinson Cancer Research Center|